AUTHOR=Hao Jianyu , Lv Yitong , Xiao Xufeng , Li Lidan , Yu Changyuan 

TITLE=Sensing antibody functions with a novel CCR8-responsive engineered cell

JOURNAL=Acta Biochimica Polonica

VOLUME=Volume 71 - 2024

YEAR=2024

URL=https://www.frontierspartnerships.org/journals/acta-biochimica-polonica/articles/10.3389/abp.2024.12185

DOI=10.3389/abp.2024.12185

ISSN=1734-154X

ABSTRACT=Human chemokine receptor 8 (CCR8) is a promising drug target for cancer and autoimmune diseases immunotherapy. Monoclonal antibody-based CCR8 targeted treatment shows significantly inhibition in tumor growth. The inhibition of CCR8 results in enhancement of antitumor immunity and patient survival rate though regulating tumor-resident regulatory T cells. Recently monoclonal antibody drug discovery against CCR8 has become a research hotspot, which also promotes the development of antibody evaluation methods. Hence, we constructed a novel engineering customized cell line HEK293-cAMP-biosensor-CCR8 combined with CCR8 and cAMP-biosensor reporter. It can be used for sensing anti-CCR8 antibody functions like specificity and biological activity as well as antibody-dependent cellmediated cytotoxicity and antibody-dependent-cellular-phagocytosis detection. We obtained a new CCR8 mAb 22H9 and verified its biological activities successfully by HEK293-cAMPbiosensor-CCR8. Our reporter cell line has high sensitivity and specificity, moreover, it offers a rapid kinetics detection platform for evaluating anti-CCR8 antibody functions.